Steve Weitman
Overview
Explore the profile of Steve Weitman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takabe H, Warnken Z, Zhang Y, Davis D, Smyth H, Kuhn J, et al.
Pharmaceutics
. 2018 May;
10(2).
PMID: 29783757
Glioblastoma multiforme (GBM) is the most common and lethal central nervous system tumor. Recently, atovaquone has shown inhibition of signal transducer and activator transcription 3, a promising target for GBM...
2.
Warnken Z, Smyth H, Davis D, Weitman S, Kuhn J, Williams 3rd R
Mol Pharm
. 2018 Feb;
15(4):1392-1402.
PMID: 29485888
Effective targeting of nasal spray deposition could improve local, systemic, and CNS drug delivery; however, this has proven to be difficult due to the anatomical features of the nasal cavity,...
3.
Trevino M, Padalecki S, Karnad A, Parra A, Weitman S, Nashawati M, et al.
J Community Med Health Educ
. 2014 Aug;
3(5):1000230.
PMID: 25152846
Background: Cancer does not occur in all ethnic and racial groups at similar rates. In addition, responses to treatment also vary in certain ethnic and racial groups. For Hispanics, the...
4.
Rowe J, Patel S, Mazo-Canola M, Parra A, Goros M, Michalek J, et al.
J Geriatr Oncol
. 2014 Feb;
5(1):65-70.
PMID: 24484720
Objective: Elderly patients with cancer are under-represented in clinical trials, and there is especially scant data on their participation in early-phase trials. In an effort to provide more data, we...
5.
Bonate P, Cunningham C, Gaynon P, Jeha S, Kadota R, Lam G, et al.
Cancer Chemother Pharmacol
. 2010 Jun;
67(4):875-90.
PMID: 20582417
Clofarabine for injection is a second-generation nucleoside analog approved in the United States (Clolar(®)) and Europe (Evoltra(®)) for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia. This report...
6.
Bonate P, Arthaud L, Cantrell Jr W, Stephenson K, Secrist 3rd J, Weitman S
Nat Rev Drug Discov
. 2006 Oct;
5(10):855-63.
PMID: 17016426
The treatment of acute leukaemias, which are the most common paediatric cancers, has improved considerably in recent decades, with complete response rates approaching approximately 90% in some cases. However, there...
7.
Mita A, Hammond L, Bonate P, Weiss G, McCreery H, Syed S, et al.
Clin Cancer Res
. 2006 Sep;
12(17):5207-15.
PMID: 16951240
Purpose: To determine the safety, tolerability, and pharmacokinetics and to seek preliminary evidence of anticancer activity of tasidotin (ILX651), a novel dolastatin analogue, when administered as a 30-minute i.v. infusion...
8.
Cunningham C, Appleman L, Kirvan-Visovatti M, Ryan D, Regan E, Vukelja S, et al.
Clin Cancer Res
. 2005 Nov;
11(21):7825-33.
PMID: 16278405
Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of tasidotin (ILX651), a dolastatin-15 analogue, when administered on days 1, 3, and 5 every 3 weeks...
9.
Ebbinghaus S, Rubin E, Hersh E, Cranmer L, Bonate P, Fram R, et al.
Clin Cancer Res
. 2005 Nov;
11(21):7807-16.
PMID: 16278403
Purpose: To determine the maximum tolerated dose, dose-limiting toxicity, and pharmacokinetics of the dolastatin-15 analogue, tasidotin (ILX651), when administered i.v. daily for 5 days every 3 weeks. Experimental Design: Thirty-six...
10.
Corey S, Elopre M, Weitman S, Rytting M, Robinson L, Rumelhart S, et al.
J Pediatr Hematol Oncol
. 2005 Mar;
27(3):166-8.
PMID: 15750451
Juvenile myelomonocytic leukemia (JMML) is the most common myeloproliferative/myelodysplastic disorder seen in children. The treatment of choice, allogeneic stem cell transplantation, provides the only known cure for the disease, but...